Pretreatment HIV-1 drug resistance testing in sub-Saharan Africa

The Lancet Infectious Diseases

Volumn 12, Issue 12, 2012, Pages 911-

  Lynen, Lutgarde ^a   Fransen, Katrien ^a   Van Griensven, Johan ^a   Colebunders, Robert ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA; ANTIVIRAL THERAPY; COST BENEFIT ANALYSIS; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS LOAD;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84869776930     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70279-7     Document Type: Letter

References (5)

1. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012, 12:307-317.
2. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11:750-759.
3. Kambugu A Pre-ART HIV resistance testing in Africa: are we there yet?. Lancet Infect Dis 2012, 12:261.
4. Lynen L, An S, Koole O, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009, 52:40-48.
5. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary?. Clin Infect Dis 2007, 44:128-134.